Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
A phase 2/3 study of fianlimab plus cemiplimab versus cem... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
A phase 2/3 study of fianlimab plus cemiplimab versus cemiplimab in patients with advanced non-small cell lung cancer with tumors expressing PD-L1 ≥50%.
0
Authors
Nicole Faulkner
18 more
Nicole Faulkner
•
Tamar Melkadze
16 more
•
Luca Paoluzzi
Published
June 1, 2024
Paper
Conversation
0
Reviews
0
Bounties
0
Sign in to comment
Add a comment...
Best
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Journal of Clinical Oncology
Topics
Medicine
Cancer Oncology
Internal Medicine
Pulmonary And Respiratory Medicine
Cancer
Show all topics
DOI
10.1200/jco.2024.42.16_suppl.tps8663
